Want to see FR:IVA full AI Analyst Report?
IVA Stock Chart & Stats
€3.82
€0.17(4.45%)
At close: 4:00 PM EDT
€3.82
€0.17(4.45%)
Day’s Range― - ―
52-Week Range€2.76 - €6.20
Previous CloseN/A
Volume253.81K
Average Volume (3M)416.07K
Market Cap
€897.69M
Enterprise Value€722.43
Total Cash (Recent Filing)€230.87M
Total Debt (Recent Filing)€59.86M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Sep 25, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding236,280,200
10 Day Avg. Volume620,713
30 Day Avg. Volume416,066
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-25.87
Price to Sales (P/S)164.59
P/FCF Ratio-7.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.69Price Target Upside127.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.66
Revenue Forecast (FY)€5.95M
Bulls Say, Bears Say
Bulls Say
Phase III NATiV3 Enrollment Completed, >90% PowerCompleting a large, well‑powered Phase III materially reduces execution risk associated with patient recruitment and primary endpoint power. Over 1,000 main‑cohort patients support statistically robust readouts, increasing the durability of clinical evidence and improving potential for regulatory confidence, partnering and licensing discussions through the readout horizon.
Material Cash Position And Runway To Key MilestonesA substantial cash balance and explicit runway to mid‑Q1 2027 (extendable to mid‑Q3 2027 with warrant exercise) provides structural financing visibility through the critical Phase III execution period. This reduces near‑term dilution pressure, supports completion of NATiV3 and related regulatory activities, and enhances optionality for strategic partnering or milestone monetization.
Clinical Differentiation And Regulatory DesignationsA differentiated pan‑PPAR mechanism with positive Phase II signals plus Breakthrough/Fast Track status are durable competitive assets: they can accelerate regulatory interactions, increase the attractiveness to partners, and support stronger commercial positioning if Phase III confirms efficacy, especially in a sizeable underdiagnosed MASH population.
Bears Say
Negative Equity And Weak Balance SheetPersistent negative equity signals accumulated losses have eroded the capital base, limiting borrowing capacity and financial flexibility. Over the medium term this elevates creditor and covenant risk, makes conditional financings more likely, and increases the probability of dilutive capital raises or restrictive deal terms if trial results or milestone cash flows are delayed or weaker than expected.
Persistent Cash Burn And Negative Operating/free Cash FlowOperating losses consistently convert into real cash outflows, producing a structural financing need until commercialization or major partnering occurs. This recurring burn compels periodic capital raises or contingent financing, raising dilution risk, constraining long‑term investment in commercialization infrastructure, and making the company reliant on milestone or warrant proceeds to bridge to value inflection points.
Safety/tolerability Risks Tied To Pan-PPAR ProfilePPAR‑γ activity–related weight gain and fluid retention are durable clinical risks that can constrain labeling, require additional monitoring, or limit uptake in comorbid populations (eg, diabetes, cardiovascular disease). Regulatory scrutiny or safety‑driven label restrictions would materially reduce addressable market and complicate payer and physician adoption even if efficacy is confirmed.
Inventiva News
IVA FAQ
What was Inventiva SA’s price range in the past 12 months?
Inventiva SA lowest stock price was €2.76 and its highest was €6.20 in the past 12 months.
What is Inventiva SA’s market cap?
Inventiva SA’s market cap is €897.69M.
When is Inventiva SA’s upcoming earnings report date?
Inventiva SA’s upcoming earnings report date is Sep 25, 2026 which is in 54 days.
How were Inventiva SA’s earnings last quarter?
Inventiva SA released its earnings results on Mar 30, 2026. The company reported -€0.926 earnings per share for the quarter, missing the consensus estimate of -€0.237 by -€0.689.
Is Inventiva SA overvalued?
According to Wall Street analysts Inventiva SA’s price is currently Undervalued.
Does Inventiva SA pay dividends?
Inventiva SA does not currently pay dividends.
What is Inventiva SA’s EPS estimate?
Inventiva SA’s EPS estimate is -0.33.
How many shares outstanding does Inventiva SA have?
Inventiva SA has 236,280,200 shares outstanding.
What happened to Inventiva SA’s price movement after its last earnings report?
Inventiva SA reported an EPS of -€0.926 in its last earnings report, missing expectations of -€0.237. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Inventiva SA?
Currently, no hedge funds are holding shares in FR:IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Inventiva SA
Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
IVA Stock 12 Month Forecast
Average Price Target
€8.69
▲(127.42% Upside)